Brand-Backed Part D Donut Hole Change Left Out Of Omnibus Package

The omnibus appropriations bill does not include a measure, backed by brand drug companies, to lower their share of Medicare Part D coverage-gap costs, and a measure on biosimilars pass-through pay that is included in the spending bill seems tailored to a specific product. Brand drug makers tried to partially undo a change that Congress recently made to Part D that increases drug makers’ share of donut-hole costs from 50 percent to 70 percent. A few options were floated over...